<DOC>
	<DOCNO>NCT00004922</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness irinotecan treating patient advance neuroendocrine tumor .</brief_summary>
	<brief_title>Irinotecan Treating Patients With Advanced Neuroendocrine Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy irinotecan term tumor response , time tumor progression , survival patient advanced high grade neuroendocrine tumor . - Evaluate dose limit nondose limit toxicity treatment regimen patient population . OUTLINE : Patients receive irinotecan IV 90 minute weekly 4 week . Treatment repeat every 6 week absence disease progression unacceptable toxicity . Patients follow death . PROJECTED ACCRUAL : A total 10-31 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Carcinoma , Merkel Cell</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic unresectable high grade neuroendocrine tumor include : Small cell carcinoma Large cell neuroendocrine carcinoma Other high grade neuroendocrine carcinoma without specification cell size No lung involvement without primary site No primary small cell lung cancer without metastasis Bidimensionally measurable disease least one lesion measure least 1 cm 1 cm High grade tumor indicate least one follow : Growth pattern suggestive neuroendocrine differentiation Mitotic rate great 15 mitoses per 10 hpf Presence abundant necrosis Immunohistochemical evidence neuroendocrine differentiation positive staining chromogranin , synaptophysin , neuron specific enolase classic microscopic appearance small cell carcinoma No low grade neuroendocrine tumor ( e.g. , carcinoid tumor , pancreatic endocrine tumor ) atypical tumor PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm^3 Granulocyte count least 1,500/mm^3 Platelet count least 75,000/mm^3 Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT great 5 time ULN Renal : Creatinine great 2.0 mg/dL Cardiovascular : No myocardial infarction within past 6 month No uncontrolled congestive heart failure require therapy Other : No active uncontrolled infection HIV negative No psychiatric disorder would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No 2 prior chemotherapy regimens No prior camptothecins Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>newly diagnose carcinoma unknown primary</keyword>
	<keyword>recurrent carcinoma unknown primary</keyword>
	<keyword>stage III neuroendocrine carcinoma skin</keyword>
	<keyword>recurrent neuroendocrine carcinoma skin</keyword>
	<keyword>neuroendocrine carcinoma</keyword>
</DOC>